Acer Therapeutics Inc

Acer Therapeutics — Investor Presentation (October 2021)

46 slides from Acer Therapeutics's investor presentation, Oct 14, 2021

  1. Slide 1: Corporate Presentation

    Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Significant Unmet Medical Needs Corporate Presentation October 14, 2021 Nasdaq: ACER Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Corporate Overview

    Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs Offices: Newton, MA and Bend, OR Headcount: 30 Founded: December 2013 Public: September 20

  4. Slide 4: Leadership Team

    Leadership Team Chris Schelling + 22 years: strategic commercial dev. & orphan BiOMARIN Harry Palmin Biol Sing + 25+ years; corporate & finance experience Novelos Matt Seibt 7 @n. Chief Commercial Officer 22 years; sales, market access & product launch Biogen Jeff Davis - 254 eee vss ofticer 25+ yea

  5. Slide 5: Investment Highlights

    5 Investment Highlights ACER Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) ACER-801 (osanetant) for the treatment of induced vasomotor sympt

  6. Slide 6: Clinical Pipeline

    6 Clinical Pipeline ACER $ Additional capital required to support planned ACER-801 and EDSIVO™ clinical trials, and to fund emetine program going forward $ $ $ PDUFA: June 5, 2022

  7. Slide 7: ACER-001 overview: small molecule with unique MOAs in various disorders

    Small molecule with unique MOAs in various disorders UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCDs: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCDs: Currently treated with RAVICTI®, BUPHENYL®, AMMON

  8. Slide 8: ACER-001 Urea Cycle Disorders

    Newborns with severe urea cycle disorders become significantly ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a tr

  9. Slide 9: ACER-001 Mechanism of Action

    9 Berry S, et al. Molecular Genetics and Metabolism 125 (2018) 251–257. ACER-001 Mechanism of Action Ammonia-scavenger therapy Alternative pathway treatment diverts nitrogen from the urea cycle to alternate routes of excretion Both RAVICTI® and BUPHENYL® metabolize to phenylbutyrate (PBA), a prodrug

  10. Slide 10: ACER-001 Unmet Need

    10 ACER-001 Unmet Need BUPHENYL®: Foul odor and foul/bitter taste; considered unpalatable1 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients took less than target dose due to tolerability Only 25% of patients indicated that they never miss

  11. Slide 11: ACER-001 Product Differentiation

    11 * Subject to FDA approval ** Shchelochkov et al., Molecular Genetics and Metabolism Reports 8 (2016) 43-47 *** RAVICTI® and BUPHENYL® pppy is based on patient weight and WAC price ACER-001 Product Differentiation

  12. Slide 12: ACER-001 Clinical & Regulatory Paths

    BE trial under fasted conditions completed in Q1 2020 BE trial under fed conditions completed in Q1 2021 Type B (pre-NDA) meeting with FDA conducted in Q2 2021 Reached agreement with FDA on initial Pediatric Study Plan (iPSP) in Q3 2021 505(b)(2) NDA for UCDs: NDA filing accepted for review by FDA i

  13. Slide 13: ACER-001 Food Effect

    13 ACER-001 Food Effect * Based on data comparison of ACER-001 under fed conditions vs. published data of NaPB under fed conditions 1 ACER-001 BE/BA Study (Part B) in healthy volunteers 2 Nakano S, et al. Sci Rep 9, 17075 (2019). https://doi.org/10.1038/s41598-019-53628-x 3 Osaka S, et al. Molecular

  14. Slide 14: ACER-001 Food Effect: In Silico Model

    14 ACER-001 Food Effect: In Silico Model Adult Virtual Patient Child Virtual Patient PAA (Safety1,2,3) uPAGN (Efficacy) 1 Mol Genet Metab. 2013 Dec; 110(4): 446-453. 2 Simell O, et al. Pediatr Res. 1986 Nov; 20(11):1117-21. 3 Thibault A, et al. Cancer. 1995 Jun 15; 75(12):2932-8. Model predicted ACE

  15. Slide 15: ACER-001 Food Effect: Summary

    Dosing and Administration for BUPHENYL®, RAVICTI® and Pheburane® are all instructed to be given with food1 There is a significant food effect with NaPB The pharmacokinetic (PK) and pharmacodynamic (PD) properties of RAVICTI® are indistinguishable in the fed or fasted states2 Dosing in a pre-meal set

  16. Slide 16: ACER-001 Value Proposition

    16 ACER-001 Value Proposition ACER-001 Taste-masked formulation designed to improve palatability of NaPB Bioequivalence trials showed ACER-001 has similar relative bioavailability to BUPHENYL® under both fasted and fed conditions Fasted (pre-meal) dosing data suggests ability to subsequently optimiz

  17. Slide 17: ACER-001 IP / Exclusivities

    17 ACER-001 IP / Exclusivities IP: Notice of Allowance (USPTO): “Palatable compositions including sodium phenylbutyrate and uses thereof,” including pharmaceutical composition claims covering ACER-001’s taste-masked, multi-particulate dosage formulation for oral administration Proprietary position i

  18. Slide 18: Agreement with Relief Therapeutics

    Signed Collaboration and License Agreement March 19, 2021 Acer received $30.0M to date ($1.0M Option Fee + $14.0M Reimbursement Payment + $10.0M First Development Payment + $5.0M 1st tranche of Second Development Payment) Relief to pay Acer additional $5.0M 2nd tranche of Second Development Payment

  19. Slide 19: ACER-801 (osanetant) overview

    ACER-801 (osanetant) is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus and KNDy neurons NK3R antagonism is an alternative to hormone replacement therap

  20. Slide 20: ACER-801 History

    Acer acquired worldwide rights to osanetant from Sanofi in December 2018 Osanetant was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 23 completed Phase 1 and 2 studies

  21. Slide 21: Vasomotor Symptoms (VMS)

    VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) 21 Vasomotor Symptoms (VMS) Roth A, et al. The Oncologist, Oct 2003, vol.8 no.5 474-487. Levine B. http://www.everydayhealth.com/menopause

  22. Slide 22: Induced Vasomotor Symptoms (iVMS)

    22 Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 years, 4

  23. Slide 23: ACER-801 Mechanism of Action

    Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d

  24. Slide 24: Clinical POC in VMS: NK3R Antagonist (Fezolinetant)

    24 Clinical POC in VMS: NK3R Antagonist Depypere H, et al. ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas for moderate-to-severe VMS ACER-801 At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Hot F

  25. Slide 25: Clinical POC in VMS: NK3R Antagonist (Pavinetant)

    25 Clinical POC in VMS: NK3R Antagonist Prague J, et al. Menopause. 2018 Aug;25(8):862-869 Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo for the treatment of polycystic ovary syndrome and menopausal hot flushes ACER-801 % change from baseline Hot flash frequency Hot fl

  26. Slide 26: ACER-801 Development Plan

    Acer is partnering with leading institutions to design and conduct clinical trials to evaluate ACER-801 in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women who are BRCA+ and have had a PBSO Men with HR+ Prost

  27. Slide 27: EDSIVO overview

    EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO’s™ potential beneficial effects in vEDS thought to be through vascular dilatation and smooth muscle relaxa

  28. Slide 28: EDSIVO Vascular Ehlers-Danlos Syndrome (vEDS)

    Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Hollow Organs (e.g. gastrointestinal, uterine) Autosomal dominant (50%); spontaneous mutations (50%) Diagnos

  29. Slide 29: EDSIVO Mechanism of Action

    Nawarskas J, et al. Cardiology in Review 2017;25: 247–253. * Kobayashi N, et al. Hypertension 2003 Nov;42(5):1004-13. EDSIVO™ has a unique pharmacological profile: β2 and β3 adrenergic receptor agonist Selective β1 and ⍺2 adrenergic receptor antagonist Intrinsic sympathomimetic activity (ISA+) Lacks

  30. Slide 30: EDSIVO BBEST Trial: COL3A1+ Subpopulation

    Efficacy: 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ pat

  31. Slide 31: EDSIVO Planned Clinical Trial

    Proposed DiSCOVER trial design* following Type B FDA meeting feedback: DiSCOVER: Decentralized Study of Celiprolol on vEDS-related Event Reduction A Phase 3, U.S.-based prospective, randomized, double-blind, placebo-controlled decentralized (virtual) clinical trial Approximately 3.5 years to complet

  32. Slide 32: EDSIVO Next Steps

    Q4 2021: Submit IND and SPA to FDA for DiSCOVER clinical trial Identify ~200 COL3A1+ patients in the U.S. for trial participation ~1,000 U.S. patients potentially available following evaluation of vEDS diagnosis code (ICD10: 79.6) Launched www.discoverceliprolol.com as an outreach tool for intereste

  33. Slide 33: Emetine Host-directed Therapy

    Host-directed Therapy Restores cellular stress response by interrupting the viral-induced MDM2-P53 loop, by shepherding RPS14 from cytosol into the nucleus, thus inhibiting viral replication Few drugs in development that are host-directed; believed to be only drug exploiting this particular MOA Mech

  34. Slide 34: Emetine background

    Emetine is one of the main alkaloids found in ipecacuanha (ipecac) root Clinically, emetine hydrochloride was originally marketed in the U.S. as a topical anti-infective in dental applications (ca 1890s by Eli Lilly and Company) Later, emetine hydrochloride for injection gained market adoption as a

  35. Slide 35: Emetine Mechanism of Action

    35 Emetine Mechanism of Action In high-density infected cells (A) emetine induces (1) nuclear translocation of RPS14 (2) followed by RPS14 binding to MDM2 (3 & 4) resulting in disruption of the interaction between MDM2-p53 (6) and MDM2- viral IE2 (5 & 7), and by RPS14 ubiquitination and degradation

  36. Slide 36: Emetine Broad-spectrum, Antiviral Activity

    36 Emetine Broad-spectrum, Antiviral Activity

  37. Slide 37: Emetine Nanomolar Potency In Vitro

    37 Emetine Nanomolar Potency In Vitro EC50 = concentration of a drug that gives half-maximal response. IC50 = concentration of an inhibitor where the response is reduced by half CC50 = 50% cytotoxic concentration *EC50 / CC50 values = μM (unless otherwise noted) **For reference, the EC50 of remdesiv

  38. Slide 38: Emetine In Vivo Efficacy Data

    38 Emetine In Vivo Efficacy Data A b C B SJL mice Number of ZIKV particles per 1 μg RNA sample 101 102 103 104 Emetine - + Day 0 Day 6 n.d. * Serum viral load (NS1 ng/mL) -10000 1000 2000 3000 Ifnar1 -/- mice VC E1 E2 MOCK % Survival BALB/c mice DPBS emetine 1 mg.kg Post-infection (Days) 0 20 40 60

  39. Slide 39: Emetine PK & Tox Data

    39 Emetine PK & Tox Data Non-clinical pharmacokinetic studies show that emetine rapidly concentrates in the tissues, reaching levels that are 1,000- to 3,000-fold greater than in the plasma Emetine has been detected in a variety of tissues, including the heart, liver, lungs, intestines, kidney, sple

  40. Slide 40: Emetine Clinical Safety

    Patients with solid tumors treated with 1 mg/kg/day emetine daily via SC injection for 10 days (cumulative dose 650 mg) did not experience any notable toxicity1 Electrocardiographic abnormalities were observed, but not often associated with significant cardiac symptoms2,3,4 T wave inversion (TWI) is

  41. Slide 41: ACER Financial Overview

    41 Cash as of June 30, 2021: $22.1M Plus $10.0M Second Development Payment in two tranches following FDA acceptance for filing and review of an NDA for ACER-001 in a UCD per Collaboration Agreement with Relief Expected to have sufficient capital to fund current operations into mid-2022$ Capitalizati

  42. Slide 42: Summary

    Summary 42 ACER Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS) ED

  43. Slide 43: Reference Slides

    Reference Slides 43

  44. Slide 44: MSUD disease overview

    MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of

  45. Slide 45: ACER-001 MSUD: Clinical POC

    45 ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at Baylor College of Medicine – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Result

  46. Slide 46: MSUD: Market Opportunity

    About 1,000 MSUD patients in the U.S., ~3,000 WW* 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD Early treatment may help reduce the rate of neuropsychological comorbidities and optimize g

Acer Therapeutics — Investor Presentation (October 2021) on 6ix